Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major

Annals of Hematology

Volumn 83, Issue 7, 2004, Pages 471-473

  Wu, K H ^a   Chang, J S ^a   Tsai, C H ^a   Peng, C T ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

thalassemia major; Combined therapy; Deferiprone; Desferrioxamine; Heart failure

Indexed keywords

ANTIARRHYTHMIC AGENT; CAPTOPRIL; DEFERIPRONE; DEFEROXAMINE; DIGOXIN; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; INOTROPIC AGENT; IRON; VASODILATOR AGENT;

ADULT; ARTICLE; CASE REPORT; CAUSE OF DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HEART FAILURE; HEART PROTECTION; HUMAN; HUMAN TISSUE; IRON DEPLETION; IRON STORAGE; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; THALASSEMIA MAJOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR AGENTS; DEFEROXAMINE; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEART FAILURE, CONGESTIVE; HEPATITIS C, CHRONIC; HUMANS; HYPOGONADISM; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PYRIDONES; SPLENECTOMY; TRICUSPID VALVE INSUFFICIENCY;

EID: 3042777499     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0820-0     Document Type: Article

References (17)

1. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516-520
2. Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361-364
3. Giardina PJ, Grady RW (2001) Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 38:360-366
4. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130-138
5. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C (2002) The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 139:50-58
6. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 121:187-189
7. Jessup M, Manno CS (1998) Diagnosis and management of iron-induced heart disease in Cooley's anemia. Ann N Y Acad Sci 850:242-250
8. Modell B, Khan M, Darlison M (2000) Survival in beta thalassemia major in the United Kingdom: data from the UK Thalassemia Register. Lancet 355:2051-2052
9. Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M (1993) Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 103:1276-1278
10. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171-2179
11. Richardson DR (2002) Deferiprone: greater efficacy at depleting myocardial than hepatic iron? Lancet 360:501-502
12. Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489-496
13. Hoffbrand V (2001) Iron chelation: 2 better than 1? Blood 97:586
14. Mavrogeni SI, Maris T, Gouliamos A, Vlahos L, Kremastinos DT (1998) Myocardial iron deposition in beta-thalassemia studies by magnetic resonance imaging. Int J Card Imaging 14:117-122
15. Olivieri NF, Brittenham BM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339:417-423
16. Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patient. Br J Haematol 101:413-415
17. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR (2002) Lack of progressive hepatic fibrosis during long term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100:1566-1569